Plexiform Neurofibroma Epidemiology Forecast

Key Highlights

 

• According to Calum Worsley (2022), Plexiform neurofibromas are usually diagnosed in early childhood, being found in approximately 30% of patients with NF1.

 

• As per Iheanacho et al. (2021), the prevalence of pediatric NF-1 varied from 1 per 960 individuals (aged 17 years) to 1 per 5,681 children (aged < 16 years).

 

• Plexiform Neurofibroma epidemiology is segmented as Total Prevalent Cases of Neurofibromatosis 1 (NF-1), Total Prevalent Cases of Plexiform Neurofibroma, Age-specific Prevalent Cases of Plexiform Neurofibroma, and Diagnosed and Treatable Cases of Plexiform Neurofibroma in the Plexiform Neurofibroma epidemiology report.

 

Request for unlocking CAGR of Plexiform Neurofibroma Epidemiology

 

DelveInsight's ‘Plexiform Neurofibroma — Epidemiology Forecast — 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Plexiform Neurofibroma epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Geography Covered

• The United States
• EU4 (Germany, Spain, Italy, and France) and the United Kingdom
• Japan

 

Study Period: 2021-2034

 

Plexiform Neurofibroma Epidemiology Disease Understanding

The DelveInsight’s Plexiform Neurofibroma (PN) epidemiology report gives a thorough understanding of Plexiform Neurofibroma by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Neurofibromatoses are a group of genetic disorders that cause tumors to form on nerve tissue. Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder caused by a mutation in the NF1 tumor suppressor gene. Individuals with NF-1 are also at an increased risk of developing other tumors. In particular, an estimated 30–50% develop plexiform neurofibromas, which involve multiple nerve fascicles and can transverse the length of nerves.

 

Plexiform neurofibroma is an uncommon variant of neurofibroma, a benign tumor of peripheral nerves (WHO grade I), arising from a proliferation of all neural elements. Plexiform neurofibromas are essentially pathognomonic of NF1 (Neurofibromatosis type 1), and unlike small sporadic localized neurofibromas and diffuse cutaneous neurofibromas, these tumors are at significant risk of eventual malignant transformation.

 

Clinically, it presents as a subcutaneous mass which feels like a "bag of worms". Most of the time, it is a superficial cutaneous/subcutaneous lesion, but it can occur almost anywhere in the body. Plexiform neurofibromas can occur anywhere in the body outside of the brain and spinal cord. They can occur on the face (including around the eye), neck, arms, legs, back, chest, abdomen, and internal organs.

 

Plexiform Neurofibroma causes significant morbidity because they are diffuse, grow alongside nerves, and may involve multiple nerve branches and plexi. The growth rate of PNs is unpredictable and there may be periods of rapid growth, followed by periods of relative inactivity. Common complications of NF1 with PN include pain, difficulty with motor functioning, and motor deficit or weakness. Rare PN-related comorbidities include vision reduction, bowel and bladder dysfunction, and obstructive sleep apnea.

 

PN sometimes occur on the skin but may also develop on larger nerves deeper in the body. They may sometimes cause symptoms including pain, weakness, numbness, bleeding, or problems with the bladder or bowels, such as urinary tract infections or constipation.

 

Plexiform Neurofibroma Diagnosis

Plexiform neurofibromas are generally diagnosed clinically with appreciation of the typical features, and histopathology is useful to exclude malignant transformation. Prenatal testing may be used to identify the existence of the NF-1 mutation in the fetus.

 

Plexiform Neurofibroma Epidemiology

The Plexiform Neurofibroma epidemiology section provides insights about historical and current Plexiform Neurofibroma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

 

• According to Calum Worsley (2022), Plexiform neurofibromas are usually diagnosed in early childhood, being found in approximately 30% of patients with NF1.

 

• As per Iheanacho et al. (2021), the prevalence of pediatric NF-1 varied from 1 per 960 individuals (aged 17 years) to 1 per 5,681 children (aged < 16 years).

 

• The disease epidemiology covered in the report provides historical as well as forecasted Plexiform Neurofibroma epidemiology [segmented as Total Prevalent Cases of Neurofibromatosis 1 (NF-1), Total Prevalent Cases of Plexiform Neurofibroma, Age-specific Prevalent Cases of Plexiform Neurofibroma, and Diagnosed and Treatable Cases of Plexiform Neurofibroma] in the 7MM covering the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan from 2021 to 2034.

 

Country Wise- Plexiform Neurofibroma Epidemiology

This section provides a glimpse of the Plexiform Neurofibroma epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

KOL- Views

To keep up with the current Plexiform Neurofibroma patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Plexiform Neurofibroma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

 

Learn how the therapeutic market will evolve and grow in the coming years: Plexiform Neurofibroma Market
 

Scope of the Plexiform Neurofibroma Epidemiology Report

• The report covers the descriptive overview of Plexiform Neurofibroma, explaining their causes, symptoms, pathophysiology, and genetic basis
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan
• The report assesses the disease risk and burden and highlights the unmet needs of Plexiform Neurofibroma
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population
• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Neurofibromatosis 1 (NF-1), Total Prevalent Cases of Plexiform Neurofibroma, Age-specific Prevalent Cases of Plexiform Neurofibroma, and Diagnosed and Treatable Cases of Plexiform Neurofibroma of Plexiform Neurofibroma

 

Plexiform Neurofibroma Epidemiology Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Plexiform Neurofibroma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Plexiform Neurofibroma
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Plexiform Neurofibroma Report Insights

• Patient Population
• Therapeutic Approaches

 

Plexiform Neurofibroma Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Plexiform Neurofibroma Epidemiology Segmentation

 

Plexiform Neurofibroma Report Assessment

• Disease Understanding
• Current Diagnosis Practices and Guidelines
• Epidemiology Trends

 

Key Questions

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Plexiform Neurofibroma?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• What is the historical Plexiform Neurofibroma patient pool in seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• What would be the forecasted patient pool of Plexiform Neurofibroma in seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Plexiform Neurofibroma?
• Out of all 7MM countries, which country would have the highest prevalent population of Plexiform Neurofibroma during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?

 

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Plexiform Neurofibroma Disease market
• To understand the future market competition in the Plexiform Neurofibroma Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Plexiform Neurofibroma Disease in the US, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Plexiform Neurofibroma Disease market
• To understand the future market competition in the Plexiform Neurofibroma Disease market